Annual CFO
-$68.79 M
-$25.82 M-60.08%
September 30, 2024
Summary
- As of February 7, 2025, OTLK annual cash flow from operations is -$68.79 million, with the most recent change of -$25.82 million (-60.08%) on September 30, 2024.
- During the last 3 years, OTLK annual CFO has fallen by -$14.54 million (-26.80%).
- OTLK annual CFO is now -879.90% below its all-time high of -$7.02 million, reached on September 30, 2014.
Performance
OTLK Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$16.98 M
+$2.53 M+12.97%
September 1, 2024
Summary
- As of February 7, 2025, OTLK quarterly cash flow from operations is -$16.98 million, with the most recent change of +$2.53 million (+12.97%) on September 1, 2024.
- Over the past year, OTLK quarterly CFO has dropped by -$3.95 million (-30.31%).
- OTLK quarterly CFO is now -21353.94% below its all-time high of $79.90 thousand, reached on September 30, 2017.
Performance
OTLK Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$68.79 M
-$4.24 M-6.57%
September 1, 2024
Summary
- As of February 7, 2025, OTLK TTM cash flow from operations is -$68.79 million, with the most recent change of -$4.24 million (-6.57%) on September 1, 2024.
- Over the past year, OTLK TTM CFO has dropped by -$21.69 million (-46.05%).
- OTLK TTM CFO is now -1776.33% below its all-time high of -$3.67 million, reached on December 31, 2014.
Performance
OTLK TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
OTLK Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -60.1% | -30.3% | -46.0% |
| 3 y3 years | -26.8% | -88.9% | -26.8% |
| 5 y5 years | -113.0% | -139.8% | -129.3% |
OTLK Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -60.1% | at low | -109.3% | +19.5% | -69.9% | at low |
| 5 y | 5-year | -116.4% | at low | -185.2% | +19.5% | -168.2% | at low |
| alltime | all time | -879.9% | at low | <-9999.0% | +19.5% | -1776.3% | at low |
Outlook Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | -$68.79 M(+60.1%) | - | - |
| Sep 2024 | - | -$16.98 M(-13.0%) | -$68.79 M(+6.6%) |
| Jun 2024 | - | -$19.51 M(+1.3%) | -$64.55 M(+10.8%) |
| Mar 2024 | - | -$19.27 M(+47.8%) | -$58.26 M(+23.7%) |
| Dec 2023 | - | -$13.03 M(+2.3%) | -$47.10 M(+9.6%) |
| Sep 2023 | -$42.97 M(-24.2%) | -$12.74 M(-3.6%) | -$42.97 M(+6.2%) |
| Jun 2023 | - | -$13.22 M(+62.9%) | -$40.48 M(-16.3%) |
| Mar 2023 | - | -$8.11 M(-8.8%) | -$48.37 M(-11.4%) |
| Dec 2022 | - | -$8.90 M(-13.2%) | -$54.59 M(-3.7%) |
| Sep 2022 | -$56.67 M(+4.5%) | -$10.25 M(-51.4%) | -$56.67 M(+2.3%) |
| Jun 2022 | - | -$21.10 M(+47.2%) | -$55.41 M(+1.7%) |
| Mar 2022 | - | -$14.33 M(+30.4%) | -$54.51 M(+5.0%) |
| Dec 2021 | - | -$10.99 M(+22.2%) | -$51.92 M(-4.3%) |
| Sep 2021 | -$54.25 M(+70.7%) | -$8.99 M(-55.5%) | -$54.25 M(-5.4%) |
| Jun 2021 | - | -$20.19 M(+71.9%) | -$57.34 M(+33.0%) |
| Mar 2021 | - | -$11.75 M(-11.8%) | -$43.10 M(+12.1%) |
| Dec 2020 | - | -$13.32 M(+10.3%) | -$38.44 M(+20.9%) |
| Sep 2020 | -$31.79 M(-1.5%) | -$12.08 M(+102.8%) | -$31.79 M(+23.9%) |
| Jun 2020 | - | -$5.96 M(-15.9%) | -$25.65 M(-14.5%) |
| Mar 2020 | - | -$7.08 M(+6.1%) | -$30.01 M(+2.8%) |
| Dec 2019 | - | -$6.67 M(+12.3%) | -$29.18 M(-9.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2019 | -$32.29 M(-2.3%) | -$5.94 M(-42.3%) | -$32.29 M(-7.1%) |
| Jun 2019 | - | -$10.31 M(+64.7%) | -$34.74 M(+5.4%) |
| Mar 2019 | - | -$6.26 M(-36.0%) | -$32.97 M(-3.5%) |
| Dec 2018 | - | -$9.78 M(+16.5%) | -$34.15 M(+3.4%) |
| Sep 2018 | -$33.04 M(+113.1%) | -$8.39 M(-1.7%) | -$33.04 M(+34.5%) |
| Jun 2018 | - | -$8.54 M(+14.7%) | -$24.57 M(+13.4%) |
| Mar 2018 | - | -$7.44 M(-14.2%) | -$21.66 M(+18.2%) |
| Dec 2017 | - | -$8.67 M(<-9900.0%) | -$18.33 M(+18.2%) |
| Sep 2017 | -$15.51 M(-65.9%) | $79.90 K(-101.4%) | -$15.51 M(-40.3%) |
| Jun 2017 | - | -$5.63 M(+37.0%) | -$25.96 M(-28.6%) |
| Mar 2017 | - | -$4.11 M(-29.6%) | -$36.36 M(-7.5%) |
| Dec 2016 | - | -$5.84 M(-43.7%) | -$39.31 M(-13.6%) |
| Sep 2016 | -$45.48 M(+65.5%) | -$10.37 M(-35.4%) | -$45.48 M(-1.4%) |
| Jun 2016 | - | -$16.04 M(+127.3%) | -$46.13 M(+15.0%) |
| Mar 2016 | - | -$7.06 M(-41.2%) | -$40.12 M(+12.0%) |
| Dec 2015 | - | -$12.01 M(+9.1%) | -$35.82 M(+30.4%) |
| Sep 2015 | -$27.48 M(+291.4%) | -$11.01 M(+9.7%) | -$27.48 M(+66.9%) |
| Jun 2015 | - | -$10.04 M(+263.6%) | -$16.46 M(+156.2%) |
| Mar 2015 | - | -$2.76 M(-24.7%) | -$6.43 M(+75.3%) |
| Dec 2014 | - | -$3.67 M | -$3.67 M |
| Sep 2014 | -$7.02 M | - | - |
FAQ
- What is Outlook Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Outlook Therapeutics?
- What is Outlook Therapeutics annual CFO year-on-year change?
- What is Outlook Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Outlook Therapeutics?
- What is Outlook Therapeutics quarterly CFO year-on-year change?
- What is Outlook Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Outlook Therapeutics?
- What is Outlook Therapeutics TTM CFO year-on-year change?
What is Outlook Therapeutics annual cash flow from operations?
The current annual CFO of OTLK is -$68.79 M
What is the all time high annual CFO for Outlook Therapeutics?
Outlook Therapeutics all-time high annual cash flow from operations is -$7.02 M
What is Outlook Therapeutics annual CFO year-on-year change?
Over the past year, OTLK annual cash flow from operations has changed by -$25.82 M (-60.08%)
What is Outlook Therapeutics quarterly cash flow from operations?
The current quarterly CFO of OTLK is -$16.98 M
What is the all time high quarterly CFO for Outlook Therapeutics?
Outlook Therapeutics all-time high quarterly cash flow from operations is $79.90 K
What is Outlook Therapeutics quarterly CFO year-on-year change?
Over the past year, OTLK quarterly cash flow from operations has changed by -$3.95 M (-30.31%)
What is Outlook Therapeutics TTM cash flow from operations?
The current TTM CFO of OTLK is -$68.79 M
What is the all time high TTM CFO for Outlook Therapeutics?
Outlook Therapeutics all-time high TTM cash flow from operations is -$3.67 M
What is Outlook Therapeutics TTM CFO year-on-year change?
Over the past year, OTLK TTM cash flow from operations has changed by -$21.69 M (-46.05%)